BioSpace News Archive

Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of aprocitentan on blood pressure lowering and proteinuria in patients with chronic kidney disease and resistant hypertension” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023.

BioUtah today announced the winners of its 2023 Life Sciences Awards. Five awards will be presented during the 2023 Mayer Brown Utah Life Sciences Summit Nov. 9 at the Salt Palace, in Salt Lake City.

Starton Therapeutics Inc. announced that it notified Healthwell Acquisition Corp. I that the Company had elected to terminate the business combination agreement among Starton, Healthwell and the other parties thereto dated as of April 27, 2023, as amended, effective immediately.

REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive data from the ongoing Phase II ALTITUDE® trial of ABBV-RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants.